Microbial translocation in HIV infection: Causes, consequences and treatment opportunities

Nature Reviews Microbiology

Volumn 10, Issue 9, 2012, Pages 655-666

  Sandler, Netanya G ^a   Douek, Daniel C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CANAKINUMAB; CHLOROQUINE; CITRULLINE; ERITORAN; ESCHERICHIA COLI PROTEIN; HYDROXYCHLOROQUINE; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAXIMIN; SEVELAMER; TOCILIZUMAB; VIRUS RNA;

ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ANTIVIRAL THERAPY; ARTERIAL WALL THICKNESS; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELIAC DISEASE; CYTOKINE PRODUCTION; DENGUE VIRUS; ENTERITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPHOSPHATEMIA; IMMUNOLOGICAL TOLERANCE; INTESTINE INJURY; INTESTINE VILLUS ATROPHY; KUPFFER CELL; LAMINA PROPRIA; MICROBIAL TRANSLOCATION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC CIRCULATION; T CELL DEPLETION; TH17 CELL; TIGHT JUNCTION; VISCERAL LEISHMANIASIS;

BACTERIAL INFECTIONS; BACTERIAL TOXINS; BACTERIAL TRANSLOCATION; GASTROINTESTINAL TRACT; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL;

EID: 84865163472     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro2848     Document Type: Review

References (167)

1. Guaraldi, G. et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin. Infect. Dis. 53, 1120-1126 (2011).
2. Hansson, G. K. & Hermansson, A. The immune system in atherosclerosis. Nature Immunol. 12, 204-212 (2011).
3. Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Rev. Immunol. 11, 519-531 (2011).
4. Pacifici, R. The immune system and bone. Arch. Biochem. Biophys. 503, 41-53 (2010).
5. Hellerstein, M. et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nature Med. 5, 83-89 (1999). (Pubitemid 29051003)
6. Hazenberg, M. D. et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 95, 249-255 (2000). (Pubitemid 30017249)
7. Kuller, L. H. et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5, e203 (2008).
8. Sandler, N. G. et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J. Infect. Dis. 203, 780-790 (2011).
9. Lederman, M. M. et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J. Infect. Dis. 204, 1217-1226 (2011).
10. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187, 1534-1543 (2003). (Pubitemid 36578959)
11. Kelly, C. J., Colgan, S. P. & Frank, D. N. Of microbes and meals: the health consequences of dietary endotoxemia. Nutr. Clin. Pract. 27, 215-225 (2012).
12. Clarke, T. B. et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nature Med. 16, 228-231 (2010).
13. Haruta, I. et al. Lipoteichoic acid may affect the pathogenesis of PBC-like bile duct damage and might be involved in systemic multifocal epithelial inflammations in chronic colitis-harboring TCRα-/-xAIM-/-mice. Autoimmunity 40, 372-379 (2007). (Pubitemid 47046482)
14. Ziegler, T. R. et al. Detectable serum flagellin and lipopolysaccharide and upregulated anti-flagellin and lipopolysaccharide immunoglobulins in human short bowel syndrome. Am. J. Physiol. Regul. Integr. Comp. Physiol. 294, R402-R410 (2008). (Pubitemid 351213744)
15. Jiang, W. et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199, 1177-1185 (2009).
16. Frances, R. et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 47, 978-985 (2008). (Pubitemid 351449689)
17. Grivennikov, S. I. & Karin, M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann. Rheum. Dis. 70 (Suppl. 1), i104-i108 (2011).
18. Raisz, L. G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318-3325 (2005). (Pubitemid 43121814)
19. Brenchley, J. M., Silvestri, G. & Douek, D. C. Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity 32, 737-742 (2010).
20. Estes, J. D. et al. Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog. 6, e1001052 (2010).
21. Chege, D. et al. Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS 25, 741-749 (2011).
22. Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Med. 12, 1365-1371 (2006). (Pubitemid 44924494)
23. + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197, 126-133 (2008). (Pubitemid 351263476)
24. Papasavvas, E. et al. Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS 23, 369-375 (2009).
25. Sun, B. et al. Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. J. Neurovirol. 16, 115-124 (2010).
26. Troseid, M., Sonnerborg, A. & Nowak, P. High mobility group box protein-1 in HIV-1 infection. Curr. HIV Res. 9, 6-10 (2010).
27. Wallet, M. A. et al. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 24, 1281-1290 (2010).
28. Burdo, T. H. et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J. Infect. Dis. 204, 1227-1236 (2011).
29. Rajasuriar, R. et al. Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor α and microbial translocation. J. Infect. Dis. 202, 1254-1264 (2010).
30. Nowroozalizadeh, S. et al. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J. Infect. Dis. 201, 1150-1154 (2010).
31. Anselmi, A. et al. Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy. Clin. Exp. Immunol. 150, 442-450 (2007). (Pubitemid 350098747)
32. Papasavvas, E. et al. Increased microbial translocation in ≤180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age. Pediatr. Infect. Dis. J. 30, 877-882 (2011).
33. Ancuta, P. et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE 3, e2516 (2008).
34. d'Ettorre, G. et al. HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. Curr. HIV Res. 9, 148-153 (2011).
35. Cassol, E. et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J. Infect. Dis. 202, 723-733 (2010).
36. Lester, R. T. et al. HIV-1 RNA dysregulates the natural TLR response to subclinical endotoxemia in Kenyan female sex-workers. PLoS ONE 4, e5644 (2009).
37. + T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J. Clin. Invest. 122, 62-69 (2012).
38. Redd, A. D. et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc. Natl Acad. Sci. USA 106, 6718-6723 (2009).
39. + T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol. 3, 172-181 (2010).
40. Bukh, A. R. et al. Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals. PLoS ONE 6, e21275 (2011).
41. Ketchum, P. A. & Novitsky, T. J. Assay of endotoxin by limulus amebocyte lysate. Methods Mol. Med. 36, 3-12 (2000).
42. Eichbaum, E. B., Harris, H. W., Kane, J. P. & Rapp, J. H. Chylomicrons can inhibit endotoxin activity in vitro. J. Surg. Res. 51, 413-416 (1991).
43. Landmann, R. et al. Human monocyte CD14 is upregulated by lipopolysaccharide. Infect. Immun. 64, 1762-1769 (1996). (Pubitemid 26129837)
44. Hiki, N. et al. Endotoxin binding and elimination by monocytes: secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria. Infect. Immun. 66, 1135-1141 (1998). (Pubitemid 28101157)
45. Nockher, W. A., Bergmann, L. & Scherberich, J. E. Increased soluble CD14 serum levels and altered CD14 expression of peripheral blood monocytes in HIV-infected patients. Clin. Exp. Immunol. 98, 369-374 (1994). (Pubitemid 24374718)
46. Eller, M. A. et al. Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans. PLoS ONE 6, e18779 (2011).
47. Merlini, E. et al. Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS ONE 6, e18580 (2011).
48. Burdo, T. H. et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J. Infect. Dis. 204, 154-163 (2011).
49. Mayne, E. et al. Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J. Acquir. Immune Defic. Syndr. 59, 340-346 (2012).
50. + T-cell response: a randomized controlled trial. J. Infect. Dis. 204, 1532-1540 (2011).
51. Funderburg, N. T. et al. Delayed reduction in CD4 T cell turnover following viral control correlates with markers of microbial translocation in treatment-naοve patients receiving RAL-based ART: preliminary results from ACTG A5248. In 18th Conf. on Retroviruses and Opportunistic Infections (Boston, Massachusetts, USA; 27 Feb-2 Mar 2011) Poster 318 (2011).
52. Meiler, C. et al. Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J. Gastroenterol. 11, 6031-6037 (2005). (Pubitemid 41749222)
53. Alhawi, M., Stewart, J., Erridge, C., Patrick, S. & Poxton, I. R. Bacteroides fragilis signals through Toll-like receptor (TLR) 2 and not through TLR4. J. Med. Microbiol. 58, 1015-1022 (2009).
54. Kramski, M. et al. Novel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation. J. Clin. Microbiol. 49, 3691-3693 (2011).
55. Bottger, E. C. Frequent contamination of Taq polymerase with DNA. Clin. Chem. 36, 1258-1259 (1990). (Pubitemid 20189281)
56. Nowak, P., Abdurahman, S., Lindkvist, A., Troseid, M. & Sonnerborg, A. Impact of HMGB1/TLR ligand complexes on HIV-1 replication: possible role for flagellin during HIV-1 infection. Int. J. Microbiol. 2012, 263836 (2012).
57. Ellis, C. L. et al. Molecular characterization of stool microbiota in HIV-infected subjects by panbacterial and order-level 16S ribosomal DNA (rDNA) quantification and correlations with immune activation. J. Acquir. Immune Defic. Syndr. 57, 363-370 (2011).
58. Kotler, D. P., Gaetz, H. P., Lange, M., Klein, E. B. & Holt, P. R. Enteropathy associated with the acquired immunodeficiency syndrome. Ann. Intern. Med. 101, 421-428 (1984). (Pubitemid 14018034)
59. Kapembwa, M. S. et al. Altered small-intestinal permeability associated with diarrhoea in human-immunodeficiency-virus-infected Caucasian and African subjects. Clin. Sci. (Lond.). 81, 327-334 (1991).
60. Zeitz, M. et al. HIV/SIV enteropathy. Ann. NY Acad. Sci. 859, 139-148 (1998). (Pubitemid 29021013)
61. Moir, S., Chun, T. W. & Fauci, A. S. Pathogenic mechanisms of HIV disease. Annu. Rev. Pathol. 6, 223-248 (2009).
62. Budhraja, M., Levendoglu, H., Kocka, F., Mangkornkanok, M. & Sherer, R. Duodenal mucosal T cell subpopulation and bacterial cultures in acquired immune deficiency syndrome. Am. J. Gastroenterol. 82, 427-431 (1987). (Pubitemid 17092987)
63. Lauritano, E. C. et al. Small intestinal bacterial overgrowth and intestinal permeability. Scand. J. Gastroenterol. 45, 1131-1132 (2010).
64. Crenn, P. et al. Plasma citrulline is a biomarker of enterocyte mass and an indicator of parenteral nutrition in HIV-infected patients. Am. J. Clin. Nutr. 90, 587-594 (2009).
65. Heise, C. et al. Human immunodeficiency virus infection of enterocytes and mononuclear cells in human jejunal mucosa. Gastroenterology 100, 1521-1527 (1991).
66. Papadia, C. et al. Plasma citrulline as a quantitative biomarker of HIV-associated villous atrophy in a tropical enteropathy population. Clin. Nutr. 29, 795-800 (2010).
67. Maresca, M. et al. The virotoxin model of HIV-1 enteropathy: involvement of GPR15/Bob and galactosylceramide in the cytopathic effects induced by HIV-1 gp120 in the HT-29-D4 intestinal cell line. J. Biomed. Sci. 10, 156-166 (2003). (Pubitemid 36173335)
68. Yu, L. C., Turner, J. R. & Buret, A. G. LPS/CD14 activation triggers SGLT-1-mediated glucose uptake and cell rescue in intestinal epithelial cells via early apoptotic signals upstream of caspase-3. Exp. Cell Res. 312, 3276-3286 (2006). (Pubitemid 44380229)
69. + T cells, epithelial apoptosis, and a mucosal barrier defect. Gastroenterology 139, 1289-1300 (2010).
70. Asmuth, D. M., Hammer, S. M. & Wanke, C. A. Physiological effects of HIV infection on human intestinal epithelial cells: an in vitro model for HIV enteropathy. AIDS 8, 205-211 (1994). (Pubitemid 24094117)
71. Nazli, A. et al. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 6, e1000852 (2010).
72. Canani, R. B. et al. Inhibitory effect of HIV-1 Tat protein on the sodium-D-glucose symporter of human intestinal epithelial cells. AIDS 20, 5-10 (2006). (Pubitemid 41818108)
73. Di Sabatino, A. et al. Intraepithelial and lamina propria lymphocytes show distinct patterns of apoptosis whereas both populations are active in Fas based cytotoxicity in coeliac disease. Gut 49, 380-386 (2001). (Pubitemid 32802573)
74. MacDonald, T. T. & Spencer, J. The role of activated T cells in transformed intestinal mucosa. Digestion 46 (Suppl. 2), 290-296 (1990). (Pubitemid 20298727)
75. Ciccocioppo, R. et al. Increased enterocyte apoptosis and Fas-Fas ligand system in celiac disease. Am. J. Clin. Pathol. 115, 494-503 (2001). (Pubitemid 32275940)
76. Kam, L. Y. & Targan, S. R. Cytokine-based therapies in inflammatory bowel disease. Curr. Opin. Gastroenterol. 15, 302-307 (1999). (Pubitemid 29377248)
77. Crenn, P., Coudray-Lucas, C., Thuillier, F., Cynober, L. & Messing, B. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 119, 1496-1505 (2000). (Pubitemid 32198675)
78. Sankaran, S. et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J. Virol. 82, 538-545 (2008). (Pubitemid 350309168)
79. Smith, A. J., Schacker, T. W., Reilly, C. S. & Haase, A. T. A role for syndecan-1 and claudin-2 in microbial translocation during HIV-1 infection. J. Acquir. Immune Defic. Syndr. 55, 306-315 (2010).
80. Kotler, D. P., Reka, S. & Clayton, F. Intestinal mucosal inflammation associated with human immunodeficiency virus infection. Dig. Dis. Sci. 38, 1119-1127 (1993). (Pubitemid 23175136)
81. Clayton, F., Snow, G., Reka, S. & Kotler, D. P. Selective depletion of rectal lamina propria rather than lymphoid aggregate CD4 lymphocytes in HIV infection. Clin. Exp. Immunol. 107, 288-292 (1997). (Pubitemid 27049254)
82. Schneider, T. et al. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group. Gut 37, 524-529 (1995).
83. + T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes. J. Virol. 72, 6646-6656 (1998). (Pubitemid 28323982)
84. Brenchley, J. M. et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112, 2826-2835 (2008).
85. + T cells in multiple tissues during acute SIV infection. Nature 434, 1093-1097 (2005). (Pubitemid 40663481)
86. + T cell activation in HIV-infected individuals. J. Immunol. 185, 5169-5179 (2010).
87. Deng, H. et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666 (1996). (Pubitemid 26197679)
88. + T cell depletion and viral replication in SIV infection. Science 280, 427-431 (1998). (Pubitemid 28208163)
89. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 77, 11708-11717 (2003). (Pubitemid 37271669)
90. Cecchinato, V. et al. Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol. 1, 279-288 (2008). (Pubitemid 351850534)
91. El Hed, A. et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J. Infect. Dis. 201, 843-854 (2010).
92. Bettelli, E., Korn, T., Oukka, M. & Kuchroo, V. K. Induction and effector functions of TH17 cells. Nature 453, 1051-1057 (2008). (Pubitemid 351871737)
93. Liu, J. Z., Pezeshki, M. & Raffatellu, M. Th17 cytokines and host-pathogen interactions at the mucosa: dichotomies of help and harm. Cytokine 48, 156-160 (2009).
94. Favre, D. et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2, 32ra36 (2010).
95. Giorgi, J. V. et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179, 859-870 (1999). (Pubitemid 29159331)
96. Simonetta, F. et al. Early and long-lasting alteration of effector CD45RA-Foxp3high regulatory T-cell homeostasis during HIV infection. J. Infect. Dis. 205, 1510-1519 (2012).
97. + regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy. J. Infect. Dis. 205, 1501-1509 (2012).
98. + mucosal NK cells during SIV infection. Blood 118, 3321-3330 (2011).
99. Feldman, M., Friedman, L. S. & Brandt, L. J. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 9th edn (Saunders, 2010).
100. Jirillo, E. et al. The role of the liver in the response to LPS: experimental and clinical findings. J. Endotoxin Res. 8, 319-327 (2002). (Pubitemid 35460666)
101. Balagopal, A. et al. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS 23, 2397-2404 (2009).
102. Sandler, N. G. et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141, 1220-1230, 1230.e1-1230.e3 (2011).
103. Fukui, H., Brauner, B., Bode, J. C. & Bode, C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J. Hepatol. 12, 162-169 (1991).
104. Vispo, E., Morello, J., Rodriguez-Novoa, S. & Soriano, V. Noncirrhotic portal hypertension in HIV infection. Curr. Opin. Infect. Dis. 24, 12-18 (2011).
105. Cesari, M. et al. Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature. AIDS Patient Care STDS 24, 697-703 (2010).
106. Stabinski, L. et al. High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir. Ther. 16, 405-411 (2011).
107. Kedzierska, K. et al. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J. Clin. Virol. 26, 247-263 (2003). (Pubitemid 36206609)
108. da Silva, B., Singer, W., Fong, I. W. & Ottaway, C. A. In vivo cytokine and neuroendocrine responses to endotoxin in human immunodeficiency virus-infected subjects. J. Infect. Dis. 180, 106-115 (1999). (Pubitemid 29293924)
109. Mureith, M. W., Chang, J. J., Lifson, J. D., Ndung'u, T. & Altfeld, M. Exposure to HIV-1-encoded Toll-like receptor 8 ligands enhances monocyte response to microbial encoded Toll-like receptor 2/4 ligands. AIDS 24, 1841-1848 (2010).
110. + T lymphocytes. J. Immunol. 168, 65-72 (2002). (Pubitemid 34014103)
111. + T cells during human endotoxemia and after stimulation with (myco) bacterial antigens: the role of cytokines. Blood 96, 2649-2654 (2000).
112. Munsaka, S. M. et al. Characteristics of activated monocyte phenotype support R5-tropic human immunodeficiency virus. Immunol. Immunogenet. Insights 1, 15-20 (2009).
113. + T cells. J. Infect. Dis. 204, 1927-1935 (2011).
114. + lymphocytes in HIV-infected patients are effector T cells accumulated in the G1 phase of the cell cycle. Eur. J. Immunol. 30, 3598-3603 (2000).
115. Kieper, W. C. et al. Recent immune status determines the source of antigens that drive homeostatic T cell expansion. J. Immunol. 174, 3158-3163 (2005). (Pubitemid 40354015)
116. + T-cell counts during antiretroviral therapy. AIDS 24, 1991-2000 (2010).
117. Lim, A. et al. Antibody and B-cell responses may control circulating lipopolysaccharide in patients with HIV infection. AIDS 25, 1379-1383 (2011).
118. + cell count. AIDS 25, 1385-1394 (2011).
119. + subjects with <50 copies/ml HIV-1 RNA. J. Clin. Virol. 46, 367-370 (2009)
120. Lien, E. et al. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood 92, 2084-2092 (1998). (Pubitemid 28446698)
121. + T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 22, 2035-2038 (2008).
122. Massanella, M. et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS 24, 959-968 (2010).
123. Marchetti, G. et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 20, 1727-1736 (2006). (Pubitemid 44299364)
124. Hofer, U. & Speck, R. F. Disturbance of the gut-associated lymphoid tissue is associated with disease progression in chronic HIV infection. Semin. Immunopathol. 31, 257-266 (2009).
125. Schacker, T. W. et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J. Clin. Invest. 110, 1133-1139 (2002). (Pubitemid 35215894)
126. Estes, J. et al. Collagen deposition limits immune reconstitution in the gut. J. Infect. Dis. 198, 456-464 (2008).
127. Estes, J. D. et al. Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J. Infect. Dis. 193, 703-712 (2006). (Pubitemid 43271504)
128. Estes, J. D. et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor β1-positive regulatory T cells and begins in early infection. J. Infect. Dis. 195, 551-561 (2007). (Pubitemid 46214398)
129. + T cell responses during suppressive ART. In 18th Conf. on Retroviruses and Opportunistic Infections (Boston, Massachusetts, USA; 27 Feb-2 Mar 2011) Poster 319 (2011).
130. Zeng, M., Haase, A. T. & Schacker, T. W. Lymphoid tissue structure and HIV-1 infection: life or death for T cells. Trends Immunol. 33, 306-314 (2012).
131. Lyons, J. L. et al. Plasma sCD14 is a biomarker associated with impaired neurocognitive test performance in attention and learning domains in HIV infection. J. Acquir. Immune Defic. Syndr. 57, 371-379 (2011).
132. Ryan, L. A. et al. Plasma levels of soluble CD14 and tumor necrosis factor-α type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. J. Infect. Dis. 184, 699-706 (2001). (Pubitemid 32826420)
133. Persidsky, Y. & Gendelman, H. E. Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J. Leukoc. Biol. 74, 691-701 (2003). (Pubitemid 38040345)
134. Currier, J. S. et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 118, e29-e35 (2008).
135. Tabib, A., Leroux, C., Mornex, J. F. & Loire, R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus- positive patients. Coron. Artery Dis. 11, 41-46 (2000). (Pubitemid 30142719)
136. Matta, F., Yaekoub, A. Y. & Stein, P. D. Human immunodeficiency virus infection and risk of venous thromboembolism. Am. J. Med. Sci. 336, 402-406 (2008).
137. Funderburg, N. T. et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 115, 161-167 (2010).
138. Marmur, J. D. et al. Identification of active tissue factor in human coronary atheroma. Circulation 94, 1226-1232 (1996). (Pubitemid 26307246)
139. Davi, G. & Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-2494 (2007).
140. + patients. 18th Conf. on Retroviruses and Opportunistic Infections (Boston, Massachusetts, USA; 27 Feb-2 Mar 2011) Poster 309 (2011).
141. + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-2296 (2006). (Pubitemid 44837777)
142. Phillips, A. N. et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir. Ther. 13, 177-187 (2008). (Pubitemid 351535369)
143. + T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 200, 761-770 (2004). (Pubitemid 39299462)
144. Mehandru, S. et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 3, e484 (2006).
145. Sun, P. P., Perianayagam, M. C. & Jaber, B. L. Endotoxin-binding affinity of sevelamer: a potential novel anti-inflammatory mechanism. Kidney Int. Suppl. S20-S25 (2009).
146. Stinghen, A. E. et al. Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purif. 29, 352-356 (2010).
147. Vlachogiannakos, J. et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment. Pharmacol. Ther. 29, 992-999 (2009).
148. Kalambokis, G. N. & Tsianos, E. V. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology 55, 655-656 (2012).
149. Pandrea, I. et al. Administration of rifaximin and sulfasalazine during acute SIV infection decreases microbial translocation and coagulation marker levels and significantly impacts viral replication. In 19th Conf. on Retroviruses and Opportunistic Infections (Seattle, Washington, USA; 5-8 Mar 2012) Paper 162 (2012).
150. Cani, P. D. et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50, 2374-2383 (2007). (Pubitemid 47512397)
151. Gori, A. et al. Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial. Mucosal Immunol. 4, 554-563 (2011).
152. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229-241 (2004). (Pubitemid 38962578)
153. Murray, S. M. et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J. Virol. 84, 12082-12086 (2010).
154. Piconi, S. et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 118, 3263-3272 (2010).
155. Lynn, M. et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J. Infect. Dis. 187, 631-639 (2003). (Pubitemid 36250027)
156. Kalil, A. C., LaRosa, S. P., Gogate, J., Lynn, M. & Opal, S. M.
157. Franklin, B. S. et al. Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. Proc. Natl Acad. Sci. USA 108, 3689-3694 (2011).
158. Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunol. 11, 373-384 (2010).
159. Kanneganti, T. D., Lamkanfi, M. & Nunez, G. Intracellular NOD-like receptors in host defense and disease. Immunity 27, 549-559 (2007). (Pubitemid 47615512)
160. Brenchley, J. M. & Douek, D. C. HIV infection and the gastrointestinal immune system. Mucosal Immunol. 1, 23-30 (2008).
161. Pastor Rojo, O. et al. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13, 269-277 (2007).
162. Gardiner, K. R. et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 36, 897-901 (1995).
163. Cho, J. H. The genetics and immunopathogenesis of inflammatory bowel disease. Nature Rev. Immunol. 8, 458-466 (2008). (Pubitemid 351733422)
164. Mandrekar, P. & Szabo, G. Signalling pathways in alcohol-induced liver inflammation. J. Hepatol. 50, 1258-1266 (2009).
165. van de Weg, C. A. et al. Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. J. Clin. Virol. 53, 38-42 (2011).
166. Santos-Oliveira, J. R. et al. Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis. PLoS Negl. Trop. Dis. 5, e1198 (2011).
167. De Palma, G. et al. Intestinal dysbiosis and reduced immunoglobulin- coated bacteria associated with coeliac disease in children. BMC Microbiol. 10, 63 (2010).